Torres-Betancourt Jesús Alejandro, Hernández-Delgadillo Rene, Cauich-Rodríguez Juan Valerio, Oliva-Rico Diego Adrián, Solis-Soto Juan Manuel, García-Cuellar Claudia María, Sánchez-Pérez Yesennia, Pineda-Aguilar Nayely, Flores-Treviño Samantha, Meester Irene, Nakagoshi-Cepeda Sergio Eduardo, Arevalo-Niño Katiushka, Nakagoshi-Cepeda María Argelia Akemi, Cabral-Romero Claudio
Laboratorio de Biología Molecular, Facultad de Odontología, Universidad Autónoma de Nuevo León, UANL, Monterrey 66455, Nuevo León, Mexico.
Instituto de Biotecnología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, UANL, Monterrey 66450, Nuevo León, Mexico.
J Funct Biomater. 2024 Oct 16;15(10):309. doi: 10.3390/jfb15100309.
Electrospun membranes (EMs) have a wide range of applications, including use as local delivery systems. In this study, we manufactured a polyurethane Tecoflex™ EM loaded with bismuth-based lipophilic nanoparticles (Tecoflex™ EMs-BisBAL NPs). The physicochemical and mechanical characteristics, along with the antitumor and bactericidal effects, were evaluated using a breast cancer cell line and methicillin-susceptible and resistant (MRSA). Drug-free Tecoflex™ EMs and Tecoflex™ EMs-BisBAL NPs had similar fiber diameters of 4.65 ± 1.42 µm and 3.95 ± 1.32 µm, respectively. Drug-free Tecoflex™ EMs did not negatively impact a human fibroblast culture, indicating that the vehicle is biocompatible. Tecoflex™ EMs-BisBAL NPs increased 94% more in size than drug-free Tecoflex™ EMs, indicating that the BisBAL NPs enhanced hydration capacity. Tecoflex™ EMs-BisBAL NPs were highly bactericidal against both methicillin-susceptible and MRSA clinical isolates, inhibiting their growth by 93.11% and 61.70%, respectively. Additionally, Tecoflex™ EMs-BisBAL NPs decreased the viability of MCF-7 tumor cells by 86% after 24 h exposure and 70.1% within 15 min. Regarding the mechanism of action of Tecoflex™ EMs-BisBAL NPs, it appears to disrupt the tumor cell membrane. In conclusion, Tecoflex™ EMs-BisBAL NPs constitute an innovative low-cost drug delivery system for human breast cancer and postoperative wound infections.
Int J Nanomedicine. 2018-10-5
J Appl Biomater Funct Mater. 2024
J Appl Biomater Funct Mater. 2022
J Nanosci Nanotechnol. 2016-1
Anticancer Agents Med Chem. 2022
Arch Pharm (Weinheim). 2024-8
Tidsskr Nor Laegeforen. 2024-4-23
Curr Drug Targets. 2023
Breast Cancer Res Treat. 2023-11
J Funct Biomater. 2023-6-25